Qingfei Huatan Formula alleviates growth suppression and inflammation-driven metabolic dysregulation in avian infectious bronchitis virus-infected broilers Authors: Ruxi Yuan, Xiaoyang Ma, Jieyu Su, Baichang Xu, Huixin Liu, Zhilong Wang, Ming Cheng, Xiaochen Ma, Shiqi Luo, Xiaoyi Jia, Bin Lu, Hongbin Si Published: 2026 ABSTRACT Avian infectious bronchitis virus (IBV) infection causes growth suppression in broilers, which has been hypothesized to involve a diversion of metabolic resources from growth toward immune defense. This study evaluated the efficacy and molecular mechanisms of Qingfei Huatan Formula (QHF) in IBV-challenged broilers. A total of 180 Yellow-feathered broilers were randomly assigned to a blank control, IBV-challenged (M41 strain), Ribavirin, and QHF dose-gradient groups. High-dose QHF intervention significantly increased body weight gain (BWG) at 14 days post-infection compared with the IBV model group (P < 0.05), reaching a level comparable to the blank control. This growth recovery was associated with reduced viral copy numbers in the trachea and lungs at 3 dpi. Mechanistically, high-dose QHF reduced serum IL-1β (P < 0.05) and increased total antioxidant capacity (T-AOC) (P < 0.05). Systems pharmacology identified quercetin, baicalein, and nobiletin as core active components, with predicted binding affinities of −8.53 kcal/mol for quercetin with TP53 and −6.38 kcal/mol for quercetin with IBV Mpro. Pearson correlation analysis showed a negative correlation between viral load/inflammatory markers and BWG. These findings indicate that QHF alleviates IBV-induced growth suppression, likely by reducing the metabolic demand of immune activation. Introduction Avian infectious bronchitis virus (IBV) continues to cause economic losses to the global broiler industry(Brimer et al., 2025). In commercial production facilities, the economic impact of IBV infection extends beyond acute mortality; it also manifests as reduced growth rate and decreased feed conversion efficiency, which contribute to production losses worldwide(Bhuiyan et al., 2021; Falchieri et al., 2024). Although vaccination programs are widely implemented, the emergence of new genotypes and recombinant variants has reduced the cross-protective efficacy of traditional vaccines(Azab et al., 2025; Vermeulen et al., 2023). In addition, global policies aimed at reducing antibiotic use have led to the phase-out of conventional synthetic drugs due to concerns over residues and antimicrobial resistance. This situation has increased the demand for phytogenic feed additives that can suppress viral loads and maintain broiler productivity(Valdez et al., 2023; Wang et al., 2024). The growth reduction observed in IBV-infected broilers has been attributed not only to direct respiratory mucosal injury but also to systemic metabolic changes driven by the host immune response(Zhao et al., 2023). IBV infection induces an increase in pro-inflammatory mediators, particularly interleukin-1β (IL-1β)(Huang et al., 2026). This inflammatory response is thought to shift metabolic resources from growth toward immune defense, leading to increased muscle protein catabolism and oxidative stress (Agrawal et al., 2023; Bouredji et al., 2022). Although synthetic antivirals can suppress viral replication to some extent, existing antiviral treatment strategies have recognized limitations in controlling the associated inflammatory response and metabolic changes (Dichtl et al., 2023). Moreover, in avian species, most antiviral drugs have only been used for research purposes and are not widely used in clinical practice due to a lack of essential pharmacokinetic and safety data (Szotowska and Ledwoń, 2024). In the search for alternatives, standardized phytogenic feed additives have shown potential due to their multi-target properties. The Qingfei Huatan Formula (QHF) is a botanical complex containing flavonoid monomers such as quercetin, baicalein, and nobiletin. Previous studies have reported that baicalein has antiviral activity against avian viruses and can improve growth performance, immunity, and antioxidant capacity in broilers(Y. J. Li et al., 2021; Zhou et al., 2019). In addition, the inclusion of Glycyrrhiza glabra (liquorice) in such formulas provides immunomodulatory and anti-inflammatory effects, helping to maintain physiological homeostasis under pathological stress(Alagawany et al., 2019). These polyphenols are hypothesized to participate in the regulation of host anabolic pathways by interacting with specific apoptotic and inflammatory signaling hubs(Y. Liu and Jiao, 2025; Vergara Nieto Á et al., 2025). However, most pharmacodynamic evaluations of herbal formulas have been limited to macroscopic phenotypic assessments, and the molecular interactions between multi-component extracts and host targets remain largely unexplored. This gap limits the precision application of phytogenic modulators in poultry nutrition. Therefore, the present study aimed to evaluate the efficacy of QHF in alleviating growth suppression in IBV-challenged broilers. By integrating in vivo phenotypic data with in silico molecular docking and correlation analyses, we investigated whether QHF components may mitigate inflammation-driven metabolic changes and their impact on growth. This research provides a basis for the potential use of QHF as a nutritional modulator in the post-antibiotic era. Materials and methods Preparation of QHF Qingfei Huatan Formula (QHF) is a compounded aqueous extract consisting of six herbal ingredients at the following fixed weight ratios: Pinelliae Rhizoma Praeparatum (Fa Ban Xia, 6 parts), Fritillariae Thunbergii Bulbus (Zhe Bei Mu, 9 parts), Citri Reticulatae Pericarpium (Chen Pi, 8 parts), Glycyrrhizae Radix et Rhizoma (Gan Cao, 7 parts), Platycodonis Radix (Jie Geng, 11 parts), and Armeniacae Semen Amarum (Ku Xing Ren, 9 parts). All crude herbs were obtained from a qualified pharmacy. The mixed herbs were soaked in 10 volumes (w/v) of distilled water for 40 min and then subjected to double decoction: the first decoction was performed with 10 volumes of water for 90 min, and the second with 8 volumes of water for 60 min. The combined decoctions were filtered through a 100-mesh sieve, centrifuged at 3,000 rpm for 10 min, and the supernatant was concentrated under reduced pressure (60°C, 0.080 MPa) to a final concentration equivalent to 1.0 g crude herb per mL. The extract was stored at 4°C until use. Virus and Reagents The pathogenic IBV M41 strain (Batch No. AV1511) was obtained from the China Institute of Veterinary Drug Control. The virus was propagated three times in SPF chicken embryos via the allantoic cavity, and the median embryo infectious dose (EID50) was determined to be 10-6.5/1 mL by the Reed–Muench method. Ribavirin (100 mg/mL) was purchased from Shanxi Taiyuan Pharmaceutical Co., Ltd. and used as the positive control. Experimental Animals and Design A total of 180 one-day-old healthy Sanhuang chicks were purchased from Guangxi Fufeng Agriculture and Animal Husbandry Group Co., Ltd. (Nanning, China). All animal procedures were reviewed and approved by the Animal Welfare and Ethics Committee of Guangxi University (Approval No.: GXU-2025-401). Chicks were housed in isolators under controlled environmental conditions with ad libitum access to feed and water. The temperature was maintained at 32–34°C for the first week and gradually reduced to 26°C thereafter. At 14 days of age, the chicks were weighed and randomly divided into 6 groups (n = 30 per group, with three replicate pens of 10 birds each): (1) blank control (NC), receiving normal saline; (2) IBV model (IBV), receiving normal saline; (3) ribavirin positive control (Ribavirin, 100 mg/0.5 L drinking water); (4) QHF high-dose (QHF-H, 4 mL/0.5 L drinking water); (5) QHF medium-dose (QHF-M, 2 mL/0.5 L drinking water); and (6) QHF low-dose (QHF-L, 1 mL/0.5 L drinking water). From 14 days of age, drug administration via drinking water was initiated on the same day as the challenge. The drugs were added to drinking water at the designated concentrations, with each group receiving 1 L per day (0.5 L in the morning and 0.5 L in the evening) for 7 consecutive days. This design represents a concurrent prophylactic/therapeutic regimen. On the day of challenge (14 days of age), all groups except the NC group were inoculated via the oculo-nasal route with 0.2 mL of IBV M41 suspension containing 105 EID50 per bird; the NC group received an equal volume of sterile saline. The experimental period lasted for 14 days. The composition and nutrient levels of the basal diet are shown in Table 1.Table 1Ingredients and analyzed composition of the basal diet.Table 1 dummy alt textIngredientsContent (%)Analyzed compositionValueCorn56.24Crude protein (%)21.13Soybean meal (43% CP)31.00Calcium (%)1.05Wheat bran4.00Total phosphorus (%)0.65Soybean oil4.30Lysine (%)1.15Dicalcium phosphate1.90Methionine (%)0.52Limestone1.30Metabolizable energy (MJ/kg)b12.35Sodium chloride0.30DL-Methionine (98%)0.20L-Lysine·HCl (78%)0.20Choline chloride0.06Premixa0.50Total100.00aThe premix provided the following per kilogram of diet: vitamin A, 10,000 IU; vitamin D3, 2,000 IU; vitamin E, 30 mg; vitamin K3, 2 mg; vitamin B1, 2 mg; vitamin B2, 5 mg; vitamin B6, 4 mg; vitamin B12, 20 mg; pantothenic acid, 15 mg; niacin, 40 mg; folic acid, 1 mg; biotin, 0.15 mg; Fe (from FeSO4·7H2O), 80 mg; Cu (from CuSO4·5H2O), 10 mg; Mn (from MnSO4·H2O), 10 mg; Zn (from ZnSO4·7H2O), 80 mg; I (from Ca(IO3)2), 0.35 mg; Se (from Na2SeO3), 0.3 mg.bMetabolizable energy was a calculated value. Table 1Ingredients and analyzed composition of the basal diet.Table 1 dummy alt textIngredientsContent (%)Analyzed compositionValueCorn56.24Crude protein (%)21.13Soybean meal (43% CP)31.00Calcium (%)1.05Wheat bran4.00Total phosphorus (%)0.65Soybean oil4.30Lysine (%)1.15Dicalcium phosphate1.90Methionine (%)0.52Limestone1.30Metabolizable energy (MJ/kg)b12.35Sodium chloride0.30DL-Methionine (98%)0.20L-Lysine·HCl (78%)0.20Choline chloride0.06Premixa0.50Total100.00aThe premix provided the following per kilogram of diet: vitamin A, 10,000 IU; vitamin D3, 2,000 IU; vitamin E, 30 mg; vitamin K3, 2 mg; vitamin B1, 2 mg; vitamin B2, 5 mg; vitamin B6, 4 mg; vitamin B12, 20 mg; pantothenic acid, 15 mg; niacin, 40 mg; folic acid, 1 mg; biotin, 0.15 mg; Fe (from FeSO4·7H2O), 80 mg; Cu (from CuSO4·5H2O), 10 mg; Mn (from MnSO4·H2O), 10 mg; Zn (from ZnSO4·7H2O), 80 mg; I (from Ca(IO3)2), 0.35 mg; Se (from Na2SeO3), 0.3 mg.bMetabolizable energy was a calculated value. Ingredients and analyzed composition of the basal diet. The premix provided the following per kilogram of diet: vitamin A, 10,000 IU; vitamin D3, 2,000 IU; vitamin E, 30 mg; vitamin K3, 2 mg; vitamin B1, 2 mg; vitamin B2, 5 mg; vitamin B6, 4 mg; vitamin B12, 20 mg; pantothenic acid, 15 mg; niacin, 40 mg; folic acid, 1 mg; biotin, 0.15 mg; Fe (from FeSO4·7H2O), 80 mg; Cu (from CuSO4·5H2O), 10 mg; Mn (from MnSO4·H2O), 10 mg; Zn (from ZnSO4·7H2O), 80 mg; I (from Ca(IO3)2), 0.35 mg; Se (from Na2SeO3), 0.3 mg. Metabolizable energy was a calculated value. Clinical scoring and sample collection Clinical signs, including depression, coughing, tracheal rales, gasping, and lethargy, were monitored daily and scored according to a standardized 5-point system (0 = normal, 4 = death) as detailed in Table 2. Body weights were recorded at 0 and 14 days post-infection (dpi) to calculate body weight gain (BWG). The percentage change in BWG was calculated as WGR (%) = [(W14 − W0) / W0] × 100%.Table 2Standardized clinical evaluation scoring system for IBV-challenged broilers.Table 2 dummy alt textScoreClinical Manifestations0Normal: Absence of clinical signs; normal behavior, respiration, and feed intake.1Mild: Occasional sneezing or snicking; normal behavior and feed intake without visible depression.2Moderate: Frequent sneezing, evident tracheal rales, and slight nasal/ocular discharge; slight lethargy with mildly reduced feed intake.3Severe: Pronounced respiratory distress (gasping, mouth breathing), severe lethargy, huddled posture, ruffled feathers, and anorexia.4Death: Mortality directly attributed to IBV infection. Table 2Standardized clinical evaluation scoring system for IBV-challenged broilers.Table 2 dummy alt textScoreClinical Manifestations0Normal: Absence of clinical signs; normal behavior, respiration, and feed intake.1Mild: Occasional sneezing or snicking; normal behavior and feed intake without visible depression.2Moderate: Frequent sneezing, evident tracheal rales, and slight nasal/ocular discharge; slight lethargy with mildly reduced feed intake.3Severe: Pronounced respiratory distress (gasping, mouth breathing), severe lethargy, huddled posture, ruffled feathers, and anorexia.4Death: Mortality directly attributed to IBV infection. Standardized clinical evaluation scoring system for IBV-challenged broilers. For tissue and serum collection, 5 chicks per group were randomly selected at each time point. At 3, 7, and 14 dpi, blood was collected from the wing vein, and serum was separated by centrifugation (3,000 × g, 10 min, 4°C) and stored at −80°C. Tracheal and lung tissues were aseptically harvested, placed in RNA preservation solution, and stored at −80°C for viral load quantification. At 14 dpi, the thymus, spleen, and bursa of Fabricius were also dissected and weighed. The immune organ index(organ weight (mg) /live body weight (g) × 100%). Quantification of viral load Total RNA was extracted from tracheal and lung tissues using an RNA extraction kit (Genstar, Beijing, China). First-strand cDNA was synthesized using a reverse transcription kit (Genstar, Beijing, China). Absolute quantification of the IBV nucleocapsid (N) gene was performed by TaqMan probe-based qRT-PCR. A standard curve was generated using 10-fold serial dilutions of a recombinant plasmid containing the target N gene sequence. Viral copy numbers were expressed as copies/μL. Measurement of serum cytokines and oxidative stress markers Serum concentrations of interferon-γ (IFN-γ), interleukin-4 (IL-4), interleukin-10 (IL-10), and interleukin-1β (IL-1β) were determined at 7 dpi using chicken-specific ELISA kits (Boyan, Nanjing, China). Oxidative stress parameters, including nitric oxide (NO), total antioxidant capacity (T-AOC), superoxide dismutase (SOD), malondialdehyde (MDA), and xanthine oxidase (XOD), were measured using micro-biochemical kits (Boyan, Nanjing; Solarbio, Beijing, China). All assays were conducted following the manufacturers' instructions. Systems pharmacology and network topological construction Active phytogenic components of QHF were screened using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database, with chemical structures cross-verified in PubChem. IBV-related disease targets were retrieved from GeneCards and OMIM databases and intersected with QHF compound targets. A "Herb-Component-Target-Disease" network was visualized using Cytoscape 3.9.0. A protein-protein interaction (PPI) network was constructed via the STRING database (confidence score ≥ 0.90) to identify core regulatory hubs. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed using the clusterProfiler package in R (P < 0.05). High-resolution 3D molecular docking prediction To predict potential binding interactions between core QHF components and key targets identified from network pharmacology, molecular docking was performed. Three representative active compounds with the highest degree centrality—quercetin, baicalein, and nobiletin—were selected as ligands. Five host hub proteins (TP53, STAT3, IL-6, AKT1, and TNF) and the IBV main protease (Mpro) were chosen as receptors based on PPI network topological analysis. Docking calculations were conducted using AutoDock software to evaluate binding affinities across all 18 ligand–receptor pairs. Subsequently, the six pairs exhibiting the lowest binding energies (i.e., the highest absolute values) were selected for detailed visualization using Discovery Studio. These pairs included quercetin–TP53, baicalein–TP53, nobiletin–TP53, baicalein–IL-6, nobiletin–AKT1, and baicalein–TNF. Statistical analysis All quantitative data are presented as mean ± standard error of the mean (SEM). Prior to analysis, data normality and homogeneity of variances were assessed using the Shapiro-Wilk test and Levene's test, respectively. Differences among groups were analyzed by one-way analysis of variance (ANOVA) followed by Tukey's post-hoc test. A Pearson correlation matrix was constructed using the corrplot package in R to evaluate relationships among viral load, serum IL-1β, T-AOC, and BWG. Statistical significance was defined as P < 0.05. All analyses were performed using SPSS 25.0 and GraphPad Prism 9.0. Results QHF alleviates clinical signs and restores growth performance in IBV-infected broilers To evaluate the protective efficacy of QHF against IBV infection, clinical signs, body weight gain, and immune organ indices were assessed. IBV-challenged birds developed typical respiratory signs, including depression, tracheal rales, and mouth breathing, with clinical scores peaking at 3–5 dpi and remaining elevated throughout the observation period. In contrast, QHF-H- and QHF-M-treated groups exhibited markedly accelerated recovery, with clinical scores declining to near zero by 12–14 dpi, significantly lower than those of the IBV and Ribavirin groups (Fig. 1B). Consistent with the clinical improvement, IBV infection caused a pronounced suppression of body weight gain (BWG) at 14 dpi compared to the NC group (P < 0.05). QHF intervention rescued this growth suppression in a dose-dependent manner, with the QHF-H group achieving BWG comparable to that of the NC group and significantly higher than that of the IBV group (P < 0.05). In contrast, Ribavirin treatment failed to restore BWG, which remained similar to that of the IBV group (P > 0.05; Fig. 1A).Fig. 1Effects of 1QHF=Qingfei Huatan Formula QHF on clinical signs and growth performance of IBV2 IBV=Avian infectious bronchitis virus-infected broilers. (A) BWG3 BWG=body weight gain at 14 days post-infection (dpi). (B) Dynamic clinical sign scores at different time points post-challenge. (C) Effects of QHF on immune organ indices (thymus, spleen, and bursa of Fabricius) of IBV-infected broilers. Data are expressed as the Mean ± SEM4 SEM=Standard Error of the Mean. Different superscript letters indicate significant differences (P < 0.05). QHF, Qingfei Huatan Formula; IBV, infectious bronchitis virus; NC, negative control.Fig 1 dummy alt text Effects of 1QHF=Qingfei Huatan Formula QHF on clinical signs and growth performance of IBV2 IBV=Avian infectious bronchitis virus-infected broilers. (A) BWG3 BWG=body weight gain at 14 days post-infection (dpi). (B) Dynamic clinical sign scores at different time points post-challenge. (C) Effects of QHF on immune organ indices (thymus, spleen, and bursa of Fabricius) of IBV-infected broilers. Data are expressed as the Mean ± SEM4 SEM=Standard Error of the Mean. Different superscript letters indicate significant differences (P < 0.05). QHF, Qingfei Huatan Formula; IBV, infectious bronchitis virus; NC, negative control. Immune organ indices measured at 7 dpi further supported the protective effects of QHF. The QHF-M group exhibited the highest thymus and bursa of Fabricius index among all groups (P < 0.05) Spleen indices showed a similar trend, with all treatment groups displaying higher values than the IBV group, although differences among the QHF, Ribavirin, and NC groups were not statistically significant (Fig. 1C). QHF suppresses viral replication and enhances humoral immune response To determine whether the clinical and growth benefits of QHF were associated with reduced viral burden, absolute viral loads in the trachea and lungs were quantified at 3, 7, and 14 dpi. In the trachea(Fig. 2A), high viral loads were detected in the IBV group across all time points, with peak levels observed at 3 dpi. Both QHF-H and QHF-M significantly reduced tracheal viral loads at 3 dpi compared to the IBV group (P < 0.05), and by 14 dpi, viral clearance was achieved in these groups, with copy numbers falling below the detection limit. The Ribavirin group showed a declining trend but did not reach complete clearance. The QHF-L group exhibited a weaker antiviral effect, with viral loads remaining significantly higher than those in the QHF-H and QHF-M groups at 14 dpi . In the lungs(Fig. 2B), viral dissemination was effectively blocked by QHF treatment. Viral loads in the QHF-H and QHF-M groups remained near or below the detection limit throughout the experiment, whereas the IBV group exhibited persistent and substantial viral burdens at 7 and 14 dpi (P < 0.05).Fig. 2Effects of QHF on respiratory viral loads and specific antibody levels. Absolute copy numbers of the IBV N gene (copies/μL) in the (A) trachea and (B) lung tissues at 3, 7, and 14 dpi. (C) Effects of QHF on serum IBV-specific IgG5 IgG=immunoglobulin G antibody levels (OD450). Data are expressed as the Mean ± SEM (n = 5). ***P < 0.01 indicates highly significant differences compared to the model group.Fig 2 dummy alt text Effects of QHF on respiratory viral loads and specific antibody levels. Absolute copy numbers of the IBV N gene (copies/μL) in the (A) trachea and (B) lung tissues at 3, 7, and 14 dpi. (C) Effects of QHF on serum IBV-specific IgG5 IgG=immunoglobulin G antibody levels (OD450). Data are expressed as the Mean ± SEM (n = 5). ***P < 0.01 indicates highly significant differences compared to the model group. Serum IBV-specific IgG antibody levels were monitored over time(Fig. 2C). In the NC group, antibody levels remained at background throughout the experiment. Following IBV challenge, antibody titers increased progressively in all infected groups. At 7 dpi, the QHF-L group exhibited the highest antibody level among all groups. By 14 dpi, the QHF-M group showed markedly elevated antibody levels compared to the IBV group, while the QHF-H and QHF-L groups maintained intermediate levels. QHF modulates systemic inflammatory and oxidative stress responses To investigate the impact of QHF on IBV-induced systemic inflammation, serum cytokine profiles were examined at 7 dpi. IBV infection provoked a robust inflammatory response, characterized by significantly elevated levels of the pro-inflammatory cytokine IL-1β and markedly suppressed levels of the anti-inflammatory cytokines IL-4, IL-10, and IFN-γ compared to the NC group (P < 0.05). QHF-H treatment significantly downregulated IL-1β compared to the IBV and Ribavirin groups (P < 0.05). Concurrently, all QHF dose groups significantly elevated IL-4, IL-10, and IFN-γ levels relative to the IBV group (P < 0.05), restoring them toward levels comparable to the NC group. The Ribavirin group showed only marginal effects on cytokine profiles (Fig. 3A).Fig. 3QHF pacifies serum inflammatory and oxidative stress indices in IBV-challenged broilers. (A) Concentrations of serum cytokines (IL-4, IFN-γ, IL-10, and IL-1β). (B) Serum oxidative stress markers, including nitric oxide (NO), T-AOC, MDA, and xanthine oxidase (XOD6 XOD=Xanthine Oxidase). Data are expressed as the Mean ± SEM. Different superscript letters indicate significant differences (P < 0.05).Fig 3 dummy alt text QHF pacifies serum inflammatory and oxidative stress indices in IBV-challenged broilers. (A) Concentrations of serum cytokines (IL-4, IFN-γ, IL-10, and IL-1β). (B) Serum oxidative stress markers, including nitric oxide (NO), T-AOC, MDA, and xanthine oxidase (XOD6 XOD=Xanthine Oxidase). Data are expressed as the Mean ± SEM. Different superscript letters indicate significant differences (P < 0.05). Oxidative stress markers were also assessed(Fig. 3B). IBV infection depressed total antioxidant capacity (T-AOC) (P > 0.05) and increased malondialdehyde (MDA) and xanthine oxidase (XOD) levels compared to the NC group (P < 0.05). QHF-H treatment significantly elevated T-AOC compared to the IBV group (P < 0.05), while all QHF dose groups significantly reduced MDA and XOD levels (P < 0.05). Nitric oxide (NO) levels were significantly decreased in the IBV group relative to the NC group, and QHF treatment significantly restored NO levels (P < 0.05). Core mechanism exploration via systems pharmacology and in silico molecular docking To explore the multi-target mechanism underlying QHF efficacy, network pharmacology analysis was performed. A total of 178 QHF-related targets and 475 IBV-associated disease targets were obtained from database screening, yielding 75 intersecting common targets considered to mediate the anti-IBV effects of QHF (Fig. 4A). Protein-protein interaction (PPI) network construction and topological analysis identified STAT3, AKT1, TNF, IL-6, VEGFA, TP53, JUN, EGFR, MYC, and IL-1β as the top 10 hub targets based on their degree centrality (Fig. 4E, F). Construction of the "Herb-Component-Target-Disease" network revealed that quercetin and baicalein exhibited the highest degree values among all active components, indicating their central roles in multi-target modulation (Fig. 4B–D). KEGG pathway enrichment analysis indicated that the common targets were significantly enriched in pathways associated with viral infection, inflammatory signaling, and apoptosis, including the IL-17 signaling pathway, PI3K-Akt signaling pathway, and NF-κB signaling pathway. GO cellular component enrichment showed that the core targets were predominantly localized to the vesicle lumen, secretory granule lumen, and cytoplasmic vesicle lumen (Fig. 4G, H).Fig. 4Network pharmacology analysis of QHF against IBV infection. (A) Venn diagram illustrating the intersection of QHF compound targets and IBV disease targets. (B) PPI7 PPI=Protein-Protein Interaction network of the intersected targets. (C) Topological analysis of the top 10 core hub targets. (D) The "Herb-Component-Target-Disease" network. (E) Degree ranking of core hub genes. (F) Degree ranking of core active phytogenic components. (G) GO8 GO=Gene Ontology cellular component enrichment analysis. (H) KEGG9 KEGG=Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. (I) TNF10 TNF=Tumor Necrosis Factor signaling pathway mapping (regulated target proteins are highlighted in red).Fig 4 dummy alt text Network pharmacology analysis of QHF against IBV infection. (A) Venn diagram illustrating the intersection of QHF compound targets and IBV disease targets. (B) PPI7 PPI=Protein-Protein Interaction network of the intersected targets. (C) Topological analysis of the top 10 core hub targets. (D) The "Herb-Component-Target-Disease" network. (E) Degree ranking of core hub genes. (F) Degree ranking of core active phytogenic components. (G) GO8 GO=Gene Ontology cellular component enrichment analysis. (H) KEGG9 KEGG=Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. (I) TNF10 TNF=Tumor Necrosis Factor signaling pathway mapping (regulated target proteins are highlighted in red). To predict binding interactions between core QHF components and key targets, molecular docking was performed using AutoDock Vina(Fig. 5A, B). Three representative active compounds (quercetin, baicalein, and nobiletin) were docked against six key proteins (TP53, STAT3, IL-6, AKT1, TNF, and IBV Mpro). All 18 ligand–receptor pairs yielded predicted binding affinities ≤ −5.0 kcal/mol, indicating favorable binding potential. Quercetin exhibited the strongest predicted binding affinity with TP53 (−8.53 kcal/mol), followed by baicalein–TP53 (−8.36 kcal/mol) and nobiletin–TP53 (−7.73 kcal/mol). Among inflammatory targets, baicalein showed high predicted affinity for TNF (−7.46 kcal/mol) and IL-6 (−6.97 kcal/mol). Nobiletin displayed a predicted affinity of −6.82 kcal/mol for AKT1. Notably, quercetin also demonstrated a moderate predicted binding affinity with the IBV main protease Mpro (−6.38 kcal/mol), suggesting a potential direct interaction with a viral enzyme.Fig. 5Cross-scale mechanistic exploration: 3D molecular docking prediction and physiological correlation matrix. (A) Predicted binding conformations of core active components (Quercetin, Baicalein, Nobiletin) with key target proteins (TP53, AKT1, STAT3, and IBV Mpro(2Q6F)). (B) Heatmap of predicted binding energies (kcal/mol) between key compounds and target proteins. (C) Pearson correlation matrix heatmap linking viral loads, serum biochemical indices, and BWG. The color scale represents the correlation coefficient (r), from −1.0 (strong negative, red) to 1.0 (strong positive, blue).Fig 5 dummy alt text Cross-scale mechanistic exploration: 3D molecular docking prediction and physiological correlation matrix. (A) Predicted binding conformations of core active components (Quercetin, Baicalein, Nobiletin) with key target proteins (TP53, AKT1, STAT3, and IBV Mpro(2Q6F)). (B) Heatmap of predicted binding energies (kcal/mol) between key compounds and target proteins. (C) Pearson correlation matrix heatmap linking viral loads, serum biochemical indices, and BWG. The color scale represents the correlation coefficient (r), from −1.0 (strong negative, red) to 1.0 (strong positive, blue). A Pearson correlation matrix was constructed to integrate macroscopic phenotypes with molecular indicators (Fig. 5C). Body weight gain showed a significant positive correlation with the antioxidant marker T-AOC and anti-inflammatory cytokines (IL-4, IL-10), and a significant negative correlation with the pro-inflammatory cytokine IL-1β and oxidative damage markers (MDA, XOD) (P < 0.05). Tracheal viral loads at 7 dpi exhibited a significant negative correlation with BWG and a significant positive correlation with IL-1β and MDA levels, supporting the hypothesis that early viral clearance limits subsequent inflammatory damage and contributes to growth recovery. Discussion QHF alleviates IBV-induced growth suppression by mitigating inflammation-driven metabolic dysregulation Avian infectious bronchitis virus (IBV) infection causes not only respiratory and renal pathology but also changes in host metabolic homeostasis that contribute to growth suppression. From a bioenergetic perspective, this production loss has been hypothesized to involve a trade-off, wherein metabolic resources are redirected from skeletal muscle accretion to support immune responses. In the current study, IBV challenge reduced body weight gain (BWG) in Yellow-feathered broilers. High-dose QHF intervention mitigated this reduction, increasing BWG compared with the IBV-challenged model at 14 days post-infection, with the QHF-H group reaching a level comparable to the blank control. Notably, while the Ribavirin positive control primarily exerts its effects through direct viral restriction, it did not significantly improve BWG in this study. This finding is consistent with the possibility that synthetic antivirals alone may not fully reverse the inflammatory and metabolic changes caused by viral infection. In contrast, QHF achieved phenotypic restoration, highlighting its potential advantage of combining antiviral activity with host metabolic modulation. The growth suppression observed during IBV replication has been linked to the metabolic demands of inflammation. Recent metabolomics evidence suggests that certain IBV strains can alter the host tricarboxylic acid (TCA) cycle, reflecting virus-induced changes in cellular energy metabolism (H. X. Liu et al., 2024). Concurrently, IBV infection has been reported to induce reactive oxygen species (ROS) accumulation and activate mitochondrial apoptosis pathways (Han et al., 2024; Li et al., 2025). This organelle-level stress may act as a trigger for the activation of innate immune sensors, including the NLRP3 inflammasome, leading to the maturation and secretion of IL-1β and subsequent pyroptotic cell death (Han et al., 2025; Huang et al., 2025). Furthermore, viral replication has been shown to upregulate the cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway in avian macrophages (Mahmoud et al., 2024). Together, these inflammatory cascades may act as catabolic signals, potentially contributing to skeletal muscle proteolysis to support cytokine production. Our findings indicate that QHF intervention attenuates this inflammatory loop. Specifically, high-dose QHF treatment reduced serum IL-1β levels and increased T-AOC compared with the IBV model group (P < 0.01), suggesting an effect on the ROS-NLRP3-IL-1β axis. Consistent with these in vivo findings, our systems pharmacology analysis identified quercetin, baicalein, and nobiletin as core active components of QHF. Molecular docking predictions further showed that quercetin has a predicted binding affinity with TP53 (-8.53 kcal/mol), a regulator of cellular apoptosis and stress responses. Given that renal-type IBV has been reported to trigger RIPK3-dependent mitochondrial apoptosis and necroptosis (Y. Li et al., 2025), QHF may exert its effects, at least in part, through pathways involving TP53 and related signaling networks. The growth recovery achieved by QHF in this study highlights the potential of flavonoid-rich formulas, which may target multiple nodes of the viral replication cycle and host inflammatory response (Da Fonseca et al., 2025; Feng et al., 2024), thereby modulating immune activation and potentially reducing metabolic demands. QHF blocks viral dissemination and quells the cytokine storm via mucosal immunomodulation The respiratory tract serves as the primary gateway and initial replication site for IBV, where localized viral amplification influences the severity of subsequent systemic pathogenesis and metabolic dysfunction (O'Dowd et al., 2024), as discussed above. In the present study, absolute viral quantification showed peak viral loads in the trachea at 3 dpi, consistent with the temporal pattern of clinical sign onset. High-dose QHF intervention reduced viral copy numbers in both the trachea and lungs at 3 dpi and achieved complete viral clearance by 14 dpi. In contrast, while the Ribavirin group showed a declining trend in tracheal viral burden, it did not prevent persistent viral replication in the lungs. The antiviral kinetics of QHF are supported by our in silico molecular docking analysis, which predicted a binding affinity (-6.38 kcal/mol) between quercetin and the IBV main protease (Mpro). Given that Mpro is a conserved enzyme essential for coronavirus polyprotein processing and replication, this theoretical interaction suggests a possible direct effect on early viral replication. However, suppressing viral replication alone may be insufficient to achieve clinical and growth recovery. Despite its antiviral activity, Ribavirin did not significantly restore BWG. This discrepancy indicates that the IBV-induced inflammatory response, once initiated, may persist independently of active viral replication. During IBV infection, resident avian macrophages can become activated, which upregulates the cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway and drives the production of pro-inflammatory cytokines such as IL-6 and NO (Mahmoud et al., 2024). The capacity of QHF to concurrently restrict viral replication and reduce serum IL-1β expression suggests a dual mechanism. By modulating macrophage activation and the COX-2/PGE2-driven inflammatory response, QHF may accelerate phenotypic recovery in a manner that pure synthetic antivirals like Ribavirin do not. Furthermore, effective viral clearance requires an adaptive and mucosal immune response. Systemically, QHF-H treatment induced higher levels of IBV-specific serum IgG at 7 dpi compared with the IBV group. This enhanced adaptive immune response is consistent with the observation that QHF protected the thymus and bursa of Fabricius from IBV-induced atrophy. Locally, the mucosal barrier, comprising tracheal ciliary clearance and secretory IgA (sIgA), is important for preventing secondary dissemination and protecting epithelial integrity (Tan et al., 2025). By limiting the early viral burden, QHF may protect the respiratory epithelium from infection-induced damage. Admittedly, mucosal sIgA concentrations and tracheal ciliary beat frequencies were not directly quantified in this study. Direct validation via tracheal explant ciliostasis assays and mucosal sIgA quantification remains a direction for future studies. Systems pharmacology uncovers the multi-target synergistic mechanisms of QHF against IBV-induced immunopathology The restoration of growth performance and immune homeostasis by QHF is unlikely to be explained by a single molecular interaction. Consistent with the multicomponent nature of phytogenic formulas, our network pharmacology analysis identified STAT3, AKT1, TNF, IL-6, VEGFA, and TP53 as primary hub genes. These targets are enriched in signaling pathways related to inflammation, apoptosis, and immune-metabolic cross-talk. This in silico network is consistent with the in vivo outcomes observed in our study, particularly the reduction in serum IL-1β, the increase in T-AOC, and the preservation of thymus and bursa of Fabricius. Molecular docking provided predicted binding affinities for these interactions. Baicalein showed predicted binding affinities for TNF (-7.46 kcal/mol) and IL-6 (-6.97 kcal/mol). This interaction provides a possible molecular basis for the attenuation of the inflammatory response, aligning with studies showing that baicalein can modulate the NF-κB/TNF-α signaling axis (Z. Wang et al., 2025; Wu et al., 2025). Furthermore, nobiletin showed a predicted binding affinity for AKT1 (-6.82 kcal/mol), a kinase in the PI3K-Akt signaling pathway. Given that AKT1 regulates cell survival and apoptosis during viral infections (Fan et al., 2024), its modulation by nobiletin may contribute to the maintenance of pulmonary tissue structure and function (Atila Uslu et al., 2025). The integration of these computational findings suggests a coordinated multi-target effect within the QHF formula. As described above, quercetin may act upstream to restrict viral replication and modulate TP53-mediated apoptosis; baicalein may inhibit inflammatory cytokines; and nobiletin may affect AKT1 signaling. This multi-target mechanism could explain why QHF achieved growth recovery that was not replicated by Ribavirin in this study. Admittedly, network pharmacology and molecular docking results are predictive. Direct validation using in vitro gene knockdown or surface plasmon resonance assays is needed. Industrial application prospects: QHF as a sustainable phytogenic intervention in the post-antibiotic era The poultry industry faces challenges from IBV due to viral mutation and antigenic drift (Guzmán et al., 2025; Zhang et al., 2025). Live-attenuated vaccines may provide limited cross-protection against emerging field strains (Strydom and Abolnik, 2025). The multi-target profile of QHF, which restricts viral replication and modulates host inflammatory and metabolic networks, may provide a broader approach compared to single-target synthetic antivirals. This positions phytogenic formulas as a potential complement to vaccination programs. Global bans on in-feed antibiotic growth promoters have increased demand for natural alternatives (Obianwuna et al., 2024). Phytogenic feed additives can enhance animal health without antimicrobial resistance or residues (El-Sabrout et al., 2023). In our study, QHF achieved BWG recovery that was not replicated by Ribavirin, indicating its potential industrial value. QHF utilizes low-cost botanical materials, and its extraction process is standardized, promoting batch-to-batch consistency. It is compatible with existing poultry watering and feeding systems. However, industrial translation presents challenges regarding compound stability during feed processing. Pelleting involves temperatures of 70–90°C, which may cause thermal degradation of flavonoids such as quercetin and baicalein. Technologies such as nanoencapsulation or micelle-based delivery systems may be considered to improve stability and bioavailability (Ahammad and Kim, 2025; Obianwuna et al., 2024). Direct validation of delivery matrices and cost-effectiveness under commercial conditions remains a direction for future research. Limitations Several limitations should be acknowledged. The evidence for metabolic reallocation is indirect, as muscle protein synthesis and whole-body energy expenditure were not measured. This study evaluated QHF only against the M41 strain in Yellow-feathered broilers, and administration was initiated simultaneously with challenge, not replicating commercial treatment scenarios. Histopathological scoring and ciliary function assessment were not performed. A formal power analysis was not conducted, and clinical scoring was not fully blinded. Conclusion Collectively, this study shows that the phytogenic formula QHF mitigates IBV-induced growth suppression in broilers, with effects involving viral restriction, attenuation of inflammatory responses, and reduction of oxidative stress. High-dose QHF intervention achieved growth recovery, significantly outperforming Ribavirin in restoring BWG. QHF restricted early viral amplification in the respiratory tract and reduced the subsequent systemic inflammatory response. These effects are associated with the core flavonoids quercetin, baicalein, and nobiletin, which may target different nodes of the viral replication cycle and host inflammatory pathways. While direct mechanistic validation remains necessary, these results suggest that QHF may serve as a sustainable alternative and a potential complement to IBV vaccination programs, providing a scientific basis for phytogenic interventions in antibiotic-free poultry production. Contributions Hongbin Si designed the study. Ruxi Yuan and Xiaoyang Ma wrote the manuscript. Jieyu Su, Baichang Xu, Huixin Liu, and Zhilong Wang collected and analyzed experimental results. ming Cheng, Xiaochen Ma, Shiqi Luo, and Xiaoyi Jia participated in the revision of the paper. Bin Lu provided guidance during the revision process. All authors contributed to the data interpretation and approved the final version of the manuscript. Acknowledgements This work was financially supported by the Guangxi Poultry Industry Innovation Team of China Agriculture Research System (CARS) (Grant No. nycytxgxcxtd-2024-19-2), the Joint Fund of the National Natural Science Foundation of China (NSFC) (Grant No. U22A20523), the 10.13039/501100012166National Key Research and Development Program of China during the 14th Five-Year Plan Period (Grant No. 2023YFD1800100), and the Natural Science Innovation Multiplication Program of Guangxi University (Grant No. 2024BZPT020). We thank the staff of the Guangxi Key Laboratory of Animal Breeding, Disease Control and Prevention for their technical support in animal experiments and laboratory testing. We also appreciate the guidance of the Animal Ethics Committee of Guangxi University on the experimental design and animal welfare implementation. CRediT authorship contribution statement Ruxi Yuan: Writing – original draft, Methodology, Data curation, Conceptualization. Xiaoyang Ma: Data curation. Jieyu Su: Writing – review & editing. Baichang Xu: Data curation. Huixin Liu: Investigation. Zhilong Wang: Writing – review & editing. Ming Cheng: Writing – review & editing. Xiaochen Ma: Data curation. Shiqi Luo: Formal analysis. Xiaoyi Jia: Resources. Bin Lu: Supervision. Hongbin Si: Supervision. Disclosures The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.